Newsfeeds - Spark Newswire

9 minute read

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday

Today, 12:04 PM

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

AEL

4 minute read

Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary

By Ragothaman Srinivasan

Today, 12:04 PM

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

ALNA

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 12:04 PM

Gainers

ARTL

1 minute read

News

Artelo Bioscience Granted U.S. Patent #11,364,202 Titled “Solid forms of cannabidiol and uses thereof”

By Benzinga Newsdesk

Today, 12:04 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11364202.PN.&OS=PN/11364202&RS=PN/11364202

ARTL

1 minute read

Artelo Biosciences Q2 EPS $(0.05) Up From $(0.11) YoY

By Bill Haddad

Today, 12:04 PM

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.05) per share. This is a 54.55 percent increase over losses of $(0.11) per share from the same period last year.

ARTL

1 minute read

Artelo Shares Jump On Favorable Preclinical Data In Cancer-Related Muscle-Wasting Syndrome

By Vandana Singh

Today, 12:04 PM

Artelo Biosciences Inc (NASDAQ: ARTL) says its ART27.13 shows promising preclinical results in protecting human muscle cells from cancer-induced muscle degeneration (cachexia)…

ARTL

1 minute read

Artelo Biosciences Reports Pre-Clinical Results For Lead Program In Cancer-Related Cachexia; Shares Move Higher

By Benzinga Newsdesk

Today, 12:04 PM

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological

ARTL

2 minute read

Artelo Expands Collaboration With Trinity College Dublin To Investigate Cellular Biology Of Fatty Acid Binding Protein (FABP) Inhibition In Cancer

By Benzinga Newsdesk

Today, 12:04 PM

ARTL

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 12:04 PM

During Friday's session, 445 companies made new 52-week lows.

AAOI

1 minute read

Artelo Biosciences Q1 EPS $(0.08) Up From $(0.14) YoY

By Benzinga Newsdesk

Today, 12:04 PM

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.08) per share. This is a 42.86 percent increase over losses of $(0.14) per share from the same period last year.

ARTL